186 related articles for article (PubMed ID: 19416226)
21. Recent developments in the treatment of heart failure: highlights from the American Heart Association's Scientific Sessions, Los Angeles, California, 3 - 7 December 2012.
von Haehling S
Expert Opin Investig Drugs; 2013 Jul; 22(7):933-7. PubMed ID: 23656525
[TBL] [Abstract][Full Text] [Related]
22. Relaxin family peptide receptors--from orphans to therapeutic targets.
van der Westhuizen ET; Halls ML; Samuel CS; Bathgate RA; Unemori EN; Sutton SW; Summers RJ
Drug Discov Today; 2008 Aug; 13(15-16):640-51. PubMed ID: 18675759
[TBL] [Abstract][Full Text] [Related]
23. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial.
Seibold JR; Korn JH; Simms R; Clements PJ; Moreland LW; Mayes MD; Furst DE; Rothfield N; Steen V; Weisman M; Collier D; Wigley FM; Merkel PA; Csuka ME; Hsu V; Rocco S; Erikson M; Hannigan J; Harkonen WS; Sanders ME
Ann Intern Med; 2000 Jun; 132(11):871-9. PubMed ID: 10836913
[TBL] [Abstract][Full Text] [Related]
24. Serelaxin a novel treatment for acute heart failure.
Castrini AI; Carubelli V; Lazzarini V; Bonadei I; Lombardi C; Metra M
Expert Rev Clin Pharmacol; 2015; 8(5):549-57. PubMed ID: 26294074
[TBL] [Abstract][Full Text] [Related]
25. Serelaxin in clinical development: past, present and future.
Unemori E
Br J Pharmacol; 2017 May; 174(10):921-932. PubMed ID: 28009437
[TBL] [Abstract][Full Text] [Related]
26. Odds still favor Novartis heart failure drug Serelaxin.
Ratner M
Nat Biotechnol; 2014 Jul; 32(7):602-3. PubMed ID: 25004210
[No Abstract] [Full Text] [Related]
27. Relaxin for the Treatment of Acute Decompensated Heart Failure: Pharmacology, Mechanisms of Action, and Clinical Evidence.
Ng TM; Goland S; Elkayam U
Cardiol Rev; 2016; 24(4):194-204. PubMed ID: 26331289
[TBL] [Abstract][Full Text] [Related]
28. Effects of serelaxin in patients admitted for acute heart failure: a meta-analysis.
Teerlink JR; Davison BA; Cotter G; Maggioni AP; Sato N; Chioncel O; Ertl G; Felker GM; Filippatos G; Greenberg BH; Pang PS; Ponikowski P; Edwards C; Senger S; Teichman SL; Nielsen OW; Voors AA; Metra M
Eur J Heart Fail; 2020 Feb; 22(2):315-329. PubMed ID: 31886953
[TBL] [Abstract][Full Text] [Related]
29. The positive inotropic effect of relaxin-2 in human atrial myocardium is preserved in end-stage heart failure: role of G(i)-phosphoinositide-3 kinase signaling.
Dschietzig T; Alexiou K; Kinkel HT; Baumann G; Matschke K; Stangl K
J Card Fail; 2011 Feb; 17(2):158-66. PubMed ID: 21300306
[TBL] [Abstract][Full Text] [Related]
30. Acute hemodynamic effects of intravenous sildenafil citrate in congestive heart failure: comparison of phosphodiesterase type-3 and -5 inhibition.
Botha P; Parry G; Dark JH; Macgowan GA
J Heart Lung Transplant; 2009 Jul; 28(7):676-82. PubMed ID: 19560695
[TBL] [Abstract][Full Text] [Related]
31. Basic progress and future therapeutic perspectives of relaxin in ischemic heart disease.
Bani D; Nistri S; Sacchi TB; Bigazzi M
Ann N Y Acad Sci; 2005 May; 1041():423-30. PubMed ID: 15956740
[TBL] [Abstract][Full Text] [Related]
32. Scientific rationale and design of a phase I safety study of relaxin in women with severe preeclampsia.
Unemori E; Sibai B; Teichman SL
Ann N Y Acad Sci; 2009 Apr; 1160():381-4. PubMed ID: 19416224
[TBL] [Abstract][Full Text] [Related]
33. [The RELAX-AHF study].
Mortara A
G Ital Cardiol (Rome); 2015 Apr; 16(4):193-7. PubMed ID: 25959752
[No Abstract] [Full Text] [Related]
34. Relaxin: a novel agent for the treatment of acute heart failure.
Wilson SS; Ayaz SI; Levy PD
Pharmacotherapy; 2015 Mar; 35(3):315-27. PubMed ID: 25759289
[TBL] [Abstract][Full Text] [Related]
35. Relaxin, a pleiotropic vasodilator for the treatment of heart failure.
Teichman SL; Unemori E; Dschietzig T; Conrad K; Voors AA; Teerlink JR; Felker GM; Metra M; Cotter G
Heart Fail Rev; 2009 Dec; 14(4):321-9. PubMed ID: 19101795
[TBL] [Abstract][Full Text] [Related]
36. Promising news about heart failure. Novel drug improves breathing and appears to extend life.
Harv Heart Lett; 2013 Apr; 23(8):6. PubMed ID: 23914394
[No Abstract] [Full Text] [Related]
37. Serelaxin: new investigational treatment in acute heart failure.
Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2013 Sep; 11(3):243-8. PubMed ID: 24289727
[TBL] [Abstract][Full Text] [Related]
38. Pharmacokinetics of conivaptan hydrochloride, a vasopressin V(1A)/V(2)-receptor antagonist, in patients with euvolemic or hypervolemic hyponatremia and with or without congestive heart failure from a prospective, 4-day open-label study.
Mao ZL; Stalker D; Keirns J
Clin Ther; 2009 Jul; 31(7):1542-50. PubMed ID: 19695403
[TBL] [Abstract][Full Text] [Related]
39. Serelaxin in acute heart failure patients with and without atrial fibrillation: a secondary analysis of the RELAX-AHF trial.
Filippatos G; Farmakis D; Metra M; Cotter G; Davison BA; Felker GM; Greenberg BH; Hua TA; Pang PS; Ponikowski P; Qian M; Severin TA; Voors AA; Teerlink JR
Clin Res Cardiol; 2017 Jun; 106(6):444-456. PubMed ID: 28150186
[TBL] [Abstract][Full Text] [Related]
40. Hemodynamic effects and safety of nesiritide in neonates with heart failure.
Simsic JM; Mahle WT; Cuadrado A; Kirshbom PM; Maher KO
J Intensive Care Med; 2008; 23(6):389-95. PubMed ID: 18805856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
